Search results
Results from the WOW.Com Content Network
HIV Drug Resistance Database, also known as Stanford HIV RT and Protease Sequence Database, is a database at Stanford University that tracks 93 common mutations of HIV.It has been recompiled in 2008 listing 93 common mutations, after its initial mutation compilation in 2007 of 80 mutations.
The Stanford HIV RT and Protease Sequence Database (also called the “HIV Drug Resistance Database”) was formed in 1998 with HIV reverse transcriptase and protease sequences from persons with well-characterized antiretroviral treatment histories, and is publicly available to query resistance mutations and genotype-treatment, genotype ...
The Stanford HIV Drug Resistance Database and the International AIDS Society publish lists of the most important of these; first year listing 80 common mutations, and the latest year 93 common mutations, and made available through the Stanford HIV RT and Protease Sequence Database. [citation needed]
As of July 2017, the WHO is implementing the Global Action Plan on HIV drug resistance 2017–2021. It is a 5-year initiative intended to help countries around the world manage HIV drug resistance. [19] Among treatment methods, the World Health Organization acknowledges the importance of successful first-line treatments. [18]
In 2014, Hader was appointed Director of the Division of Global HIV and TB at the US Centers for Disease Control and Prevention (CDC). [2] She helped implement the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) to collect more data and increase global access to life-saving HIV treatment.
HIV Resistance Response Database Initiative (RDI) was formed in 2002 to use artificial intelligence (AI) to predict how patients will respond to HIV drugs using data from more 250,000 patients from around 50 countries around the world. The RDI used its models to power its HIV Treatment Response Prediction System (HIV-TRePS).
Resistance ranged from 3.9% to 8.6% and reached 19.6% among people who have received and transitioned to a dolutegravir-containing antiretroviral therapy (ART) regimen to combat high HIV viral loads.
Baseline resistance is the presence of resistance mutations in patients who have never been treated before for HIV. In countries with a high rate of baseline resistance, resistance testing is recommended before starting treatment; or, if the initiation of treatment is urgent, then a "best guess" treatment regimen should be started, which is ...